Stockscreener 앱 받기
18.13
1.36%
-0.25
전일 마감가:
$18.38
열려 있는:
$18.2
하루 거래량:
684.71K
Relative Volume:
0.65
시가총액:
$1.11B
수익:
-
순이익/손실:
$-221.04M
주가수익비율:
-4.8811
EPS:
-3.7143
순현금흐름:
$-178.65M
1주 성능:
+2.84%
1개월 성능:
+50.46%
6개월 성능:
+66.33%
1년 성능:
+131.25%
1일 변동 폭
$17.27
$18.33
1주일 범위
$17.27
$18.77
52주 변동 폭
$5.68
$19.43
쿨리난 온콜로지 Stock (CGEM) Company Profile
명칭
Cullinan Therapeutics Inc
전화
617-410-4650
주소
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
18.13 | 1.11B | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
쿨리난 온콜로지 Stock (CGEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 개시 | Citigroup | Buy |
| 2026-02-02 | 개시 | Guggenheim | Buy |
| 2025-08-21 | 재개 | H.C. Wainwright | Buy |
| 2025-06-11 | 재개 | Stifel | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-05-01 | 개시 | Stifel | Buy |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-06-15 | 개시 | TD Cowen | Outperform |
| 2022-11-21 | 개시 | BTIG Research | Buy |
| 2021-04-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 개시 | Evercore ISI | Outperform |
| 2021-02-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 개시 | SVB Leerink | Outperform |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
모두보기
쿨리난 온콜로지 주식(CGEM)의 최신 뉴스
Cullinan CSO sells shares, exercises options | CGEM Insider Trading - Stock Titan
Enterprise value to EBIT forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
Price to sales forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
CGEM (NASDAQ) insider resale notice: 8,000 shares proposed, prior 10b5-1 sales noted - Stock Titan
CGEMCullinan Therapeutics Inc Latest SEC Filings - Finviz
Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase - Stock Titan
Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60 - Stock Titan
EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine - Barchart.com
Cullinan Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGEM) - TradingView
CGEM Forecast — Price Target — Prediction for 2027 - TradingView
Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data – Has The Bull Case Changed? - Sahm
Cullinan Therapeutics Inc (CGEM) Valuation: PE, PB & Fair Value Analysis - TradingKey
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com - Investing.com Australia
Cullinan Oncology stock hits 52-week high at $17.97 - Investing.com UK
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes - Yahoo Finance
Cullinan Therapeutics Inc (CGEM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cullinan Therapeutics (CGEM) Citi’s 2026 Virtual Oncology Leadership Summit Summary - Quartr
Cullinan Therapeutics (CGEM) TD Cowen 46th Annual Health Care Conference Summary - Quartr
CULLINAN THERAPEUTICS INC (CGEM) Stock Chart - ChartMill
Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant - Stock Titan
Cullinan Therapeutics (CGEM) grants director 25,319 stock options - Stock Titan
Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM) - Stock Titan
Cullinan Therapeutics (CGEM) director receives stock options for 25,319 shares - Stock Titan
Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options - Stock Titan
Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike - Stock Titan
Cullinan Therapeutics senior leaders use personal experience to inspire clinical development - Traders Union
Cullinan Therapeutics Inc (CGEM) Institutional Confidence - TradingKey
Cullinan Therapeutics Inc (CGEM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cullinan Therapeutics Inc (CGEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cullinan Therapeutics Inc (CGEM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cullinan Therapeutics Inc (CGEM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cullinan Therapeutics Inc (CGEM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cullinan Therapeutics Inc (CGEM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com
Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay - Stock Titan
Cullinan Therapeutics CSO to join MITCEO Conference panel on advancing patient medicines - Traders Union
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and Viridian Therapeutics (VRDN) - The Globe and Mail
CGEM Reiterated by Wedbush -- Price Target Maintained at $37 - GuruFocus
Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) - Seeking Alpha
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $33 to $46 - Moomoo
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Cullinan Therapeutics reports remissions in SLE, RA with CLN-978 - scanx.trade
William Blair reiterates Cullinan Oncology stock rating on trial data By Investing.com - Investing.com South Africa
William Blair reiterates Cullinan Oncology stock rating on trial data - Investing.com
CGEM: CLN-978 and velinotamig show breakthrough efficacy and safety in refractory autoimmune diseases - TradingView
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune DiseasesSlideshow (NASDAQ:CGEM) 2026-06-10 - Seeking Alpha
Cullinan Therapeutics (CGEM) Reports Positive Clinical Developme - GuruFocus
CGEM: T cell engagers show robust efficacy in RA and SLE, with expanded trials planned for 2027 - TradingView
Cullinan reports clinical data for autoimmune drug candidates - Investing.com UK
쿨리난 온콜로지 (CGEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):